Replies to post #203263 on Biotech Values

[DewDiligence]

Lucentis will soon be available in a pre-filled syringe (in the US market):

http://finance.yahoo.com/news/fda-approves-genentech-lucentis-ranibizumab-162700437.html

[DewDiligence]

FDA approves Lucentis for myopic choroidal neovascularization, a rare complication of severe near-sightedness:

http://finance.yahoo.com/news/fda-approves-genentech-lucentis-ranibizumab-230800100.html

The approval is based on a single phase-3 trial where the control arm was treatment with Visudyne! This is the first FDA approval for this indication.

[DewDiligence]

PFNX drops development of Lucentis/Neulasta FoBs:

https://www.prnewswire.com/news-releases/pfenex-reports-third-quarter-2017-results-interim-pk-data-from-pf708-study-completion-of-process-development-milestone-on-jazz-program-and-provides-business-update-300553252.html

Pfenex has completed a strategic review of PF582 and PF529, biosimilar product candidates to Lucentis and Neulasta, respectively. ...While the market opportunities remain attractive, Pfenex has decided to pause development activities on PF582 and PF529 and focus development efforts elsewhere within the product portfolio until strategic partnerships for these candidates are forged.

LOL re the word, pause.